宏壮病治疗和骨:一个双向的关系
Sabrina Chiloiro1,2, Chiara Palumbo3,4, Antonella Giampietro3,4
1School of Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy. sabrina.chiloiro@unicatt.it.
Pituitary
|November 8, 2025
概括
由于生长激素 (GH) 和胰岛素类生长因子I (IGF-I) 的过量,壮症患者的脊椎骨折风险更高. 索马托斯塔丁受体连接体可能会减少骨折发生率并影响骨代谢.
科学领域:
- 内分泌学 在内分泌学.
- 骨的新陈代谢 骨的新陈代谢
- 药理学 药理学是指药理学的学科.
背景情况:
- 巨症是由生长激素 (GH) 和胰岛素类生长因子I (IGF-I) 过量的分泌引起的.
- 过多的GH和IGF-I会导致系统性并发症,包括增加脆弱性脊椎骨折 (VFs) 的风险.
- 长期暴露于高GH/IGF-I水平是已知的骨折风险因素.
研究的目的:
- 审查用GH/IGF-I降低药物治疗的壮病患者中脊椎骨折 (VFs) 的发生率.
- 探索这些治疗对骨代谢的潜在影响.
- 总结关于GH/IGF-I降低药物与骨之间的分子相互作用的临床前数据.
主要方法:
- 关于脊椎骨折发生率在壮症中的研究的文献综述.
- 对GH/IGF-I降低药物对骨代谢的影响数据的分析.
- 包括关于分子通路的临床前数据.
主要成果:
- 第一代和第二代体静止素受体连接体 (SRLs) 显示,脊椎骨折 (i-VFs) 的发生率有所降低.
- SRL对骨代谢的直接影响尚未完全报告.
- 临床前数据可能会阐明这些药物与骨健康相关的分子机制.
结论:
- 降低GH/IGF-I的药物,特别是SRLs,似乎可以减少脊椎骨折发生率.
- 需要进一步的研究来了解这些疗法对骨代谢和相关分子通路的直接影响.
关键词:
壮成长是一种壮成长.骨头 骨头 骨头 骨头第一代体静止素受体连接体 (octreotide,lanreotide) 的使用GH GH GH GH 的意思是什么?增生激素受体对手 (pegvisomant) 的使用国际分支基金 (IGF-I) 的第一部分.第二代体静止素受体连接体 (帕西里奥提德)脊椎骨折是指脊椎骨折的发生.更多相关视频
13:16Computed Tomography and Optical Imaging of Osteogenesis-angiogenesis Coupling to Assess Integration of Cranial Bone Autografts and Allografts
Published on: December 22, 2015
11.9K
05:55Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
Published on: September 27, 2024
901
相关概念视频
Hormones and Bone Tissue
3.6K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
3.6K
Bone Remodeling
40.2K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
40.2K
Osteoclasts in Bone Remodeling
3.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.9K
Bone Disorders
5.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.0K
Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
